NT5E and neoplasm: By screening the efficacy and function of each drug alone and in various combinations using clinically relevant doses, we identified luteolin and quercetin as potent antagonists of paclitaxel-enriched CD73 and CSCs, and their combination with paclitaxel effectively reducing TNBC tumor growth and promoting anti-tumor immunity in vivo.